Literature DB >> 32082804

Prognostic factors for stage I lung adenocarcinoma and surgical management of subsolid nodules.

Gökhan Kocaman1, Mustafa Bülent Yenigün1, Atilla Halil Elhan2, Serpil Dizbay Sak3, Elvin Hamzayev1, Serkan Enön1, Ayten Kayı Cangır1, Cabir Yüksel1.   

Abstract

BACKGROUND: This study aims to identify the prognostic factors for stage I lung adenocarcinoma and to evaluate the surgical management of subsolid nodules.
METHODS: The study included 133 patients (90 males, 43 females; mean age 64.9 years; range, 29 to 82 years) who had undergone operation in our clinic for stage I lung adenocarcinoma between January 2007 and December 2015. Clinical, radiological and pathological data were retrospectively evaluated and their effects on recurrence and survival were examined by Kaplan-Meier and Cox regression analyses.
RESULTS: Comparing the histopathological tumor types according to the pathological tumors size, we determined that the prevalence of invasive adenocarcinoma significantly increased with increasing tumor size (p<0.001). For all nodules, a tumor disappearance rate lower than 25% negatively influenced disease-free survival and a maximum standardized uptake value higher than 5.6 negatively influenced overall survival (p=0.027 for both). The grouping, which was performed considering the maximum standardized uptake value 5.6 as the cut-off value, was an independent prognostic factor for overall survival (hazard ratio: 5.973, 95% confidence interval: 1.186-30.073, p=0.03). Five-year overall survival rate was statistically significantly higher in patients who underwent wedge resection or segmentectomy for subsolid nodules compared to those who underwent lobectomy (100% vs. 79.3%, p=0.044).
CONCLUSION: Sublobar resections can be safely performed in subsolid nodules smaller than 2 cm in diameter with tumor disappearance rate ≥25% and maximum standardized uptake value ≤5.6.
Copyright © 2018, Turkish Society of Cardiovascular Surgery.

Entities:  

Keywords:  Adenocarcinoma; stage I; subsolid nodules

Year:  2018        PMID: 32082804      PMCID: PMC7018191          DOI: 10.5606/tgkdc.dergisi.2018.15846

Source DB:  PubMed          Journal:  Turk Gogus Kalp Damar Cerrahisi Derg        ISSN: 1301-5680            Impact factor:   0.332


  20 in total

1.  Intentional limited resection for small peripheral lung cancer based on intraoperative pathologic exploration.

Authors:  Takehiro Watanabe; Akira Okada; Takayuki Imakiire; Terumoto Koike; Tatsuhiko Hirono
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2005-01

2.  Limited resection trial for pulmonary ground-glass opacity nodules: fifty-case experience.

Authors:  Junji Yoshida; Kanji Nagai; Tomoyuki Yokose; Mitsuyo Nishimura; Ryutaro Kakinuma; Hironobu Ohmatsu; Yutaka Nishiwaki
Journal:  J Thorac Cardiovasc Surg       Date:  2005-05       Impact factor: 5.209

3.  Segmentectomy versus lobectomy for clinical stage IA lung adenocarcinoma.

Authors:  Morihito Okada; Takahiro Mimae; Yasuhiro Tsutani; Haruhiko Nakayama; Sakae Okumura; Masahiro Yoshimura; Yoshihiro Miyata
Journal:  Ann Cardiothorac Surg       Date:  2014-03

4.  Early results of a prospective study of limited resection for bronchioloalveolar adenocarcinoma of the lung.

Authors:  Y Yamato; M Tsuchida; T Watanabe; T Aoki; N Koizumi; H Umezu; J Hayashi
Journal:  Ann Thorac Surg       Date:  2001-03       Impact factor: 4.330

5.  Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification in stage IB lung adenocarcinoma.

Authors:  C-h Xu; W Wang; Y Wei; H-d Hu; J Zou; J Yan; L-k Yu; R-s Yang; Y Wang
Journal:  Eur J Surg Oncol       Date:  2015-06-23       Impact factor: 4.424

Review 6.  International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.

Authors:  William D Travis; Elisabeth Brambilla; Masayuki Noguchi; Andrew G Nicholson; Kim R Geisinger; Yasushi Yatabe; David G Beer; Charles A Powell; Gregory J Riely; Paul E Van Schil; Kavita Garg; John H M Austin; Hisao Asamura; Valerie W Rusch; Fred R Hirsch; Giorgio Scagliotti; Tetsuya Mitsudomi; Rudolf M Huber; Yuichi Ishikawa; James Jett; Montserrat Sanchez-Cespedes; Jean-Paul Sculier; Takashi Takahashi; Masahiro Tsuboi; Johan Vansteenkiste; Ignacio Wistuba; Pan-Chyr Yang; Denise Aberle; Christian Brambilla; Douglas Flieder; Wilbur Franklin; Adi Gazdar; Michael Gould; Philip Hasleton; Douglas Henderson; Bruce Johnson; David Johnson; Keith Kerr; Keiko Kuriyama; Jin Soo Lee; Vincent A Miller; Iver Petersen; Victor Roggli; Rafael Rosell; Nagahiro Saijo; Erik Thunnissen; Ming Tsao; David Yankelewitz
Journal:  J Thorac Oncol       Date:  2011-02       Impact factor: 15.609

7.  Efficacy of thoracoscopic resection for multifocal bronchioloalveolar carcinoma showing pure ground-glass opacities of 20 mm or less in diameter.

Authors:  Mingyon Mun; Tadasu Kohno
Journal:  J Thorac Cardiovasc Surg       Date:  2007-10       Impact factor: 5.209

8.  Relationship between lung adenocarcinoma histological subtype and patient prognosis.

Authors:  Halide Nur Urer; Celalettin Ibrahim Kocaturk; Mehmet Zeki Gunluoglu; Naciye Arda; Mehmet Ali Bedirhan; Neslihan Fener; Seyyit Ibrahim Dincer
Journal:  Ann Thorac Cardiovasc Surg       Date:  2013-01-31       Impact factor: 1.520

9.  Tumor invasiveness as defined by the newly proposed IASLC/ATS/ERS classification has prognostic significance for pathologic stage IA lung adenocarcinoma and can be predicted by radiologic parameters.

Authors:  Mamoru Takahashi; Yoshiki Shigematsu; Makoto Ohta; Hironobu Tokumasu; Tadashi Matsukura; Takashi Hirai
Journal:  J Thorac Cardiovasc Surg       Date:  2013-10-13       Impact factor: 5.209

10.  Predictors of Recurrence after Curative Resection in Patients with Early-Stage Non-Small Cell Lung Cancer.

Authors:  Sang Hee Lee; Eun Jung Jo; Jung Seop Eom; Jeong Ha Mok; Mi Hyun Kim; Kwangha Lee; Ki Uk Kim; Hye-Kyung Park; Chang Hun Lee; Yeong Dae Kim; Min Ki Lee
Journal:  Tuberc Respir Dis (Seoul)       Date:  2015-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.